Acute hypoxic exposure can induce functional brain impairment, driven by molecular mechanisms including mitochondrial dysfunction, intracellular calcium overload, glial cell activation and inflammatory responses, blood-brain barrier disruption, and alterated cerebral blood flow. Acetazolamide, a broad-spectrum carbonic anhydrase inhibitor, is a standard clinical treatment and remains the only medication approved by the Food and Drug Administration for the prevention and treatment of acute mountain sickness. Substantial evidence confirms that under acute hypoxic exposure, acetazolamide exerts multi-level neuroprotective effects on brain tissue by inhibiting carbonic anhydrase VB and other isoforms. These protective mechanisms involve preserving mitochondrial integrity, regulating calcium homeostasis and pH balance, modulating glial cell activity to mitigate neuroinflammation, maintaining blood-brain barrier structure integrity, and improving cerebral perfusion through cerebrovascular regulation. This article reviewed the molecular pathological mechanisms of hypoxia-induced nervous system damage, summarized the pharmacological properties and neuroprotective effects of acetazolamide, and provided a theoretical basis for therapeutic interventions against high-altitude hypoxic neural injury.

Acute hypoxic exposure can induce functional brain impairment, driven by molecular mechanisms including mitochondrial dysfunction, intracellular calcium overload, glial cell activation and inflammatory responses, blood-brain barrier disruption, and alterated cerebral blood flow. Acetazolamide, a broad-spectrum carbonic anhydrase inhibitor, is a standard clinical treatment and remains the only medication approved by the Food and Drug Administration for the prevention and treatment of acute mountain sickness. Substantial evidence confirms that under acute hypoxic exposure, acetazolamide exerts multi-level neuroprotective effects on brain tissue by inhibiting carbonic anhydrase VB and other isoforms. These protective mechanisms involve preserving mitochondrial integrity, regulating calcium homeostasis and pH balance, modulating glial cell activity to mitigate neuroinflammation, maintaining blood-brain barrier structure integrity, and improving cerebral perfusion through cerebrovascular regulation. This article reviewed the molecular pathological mechanisms of hypoxia-induced nervous system damage, summarized the pharmacological properties and neuroprotective effects of acetazolamide, and provided a theoretical basis for therapeutic interventions against high-altitude hypoxic neural injury.

Background Acute hypoxia exposure can impair synaptic transmission in hippocampal neurons and disrupt neural network function. However, the specific molecular mechanisms underlying hypoxia-induced synaptic vesicle dysfunction remain not fully elucidated. Objective To investigate the molecular mechanisms underlying acute hypoxia-induced synaptic vesicle dysfunction in human hippocampal neuronal cells (HPPNCs) with a particular focus on the regulatory role of long non-coding RNA (lncRNA) FTX in the miR-137-3p/soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex axis. Methods An acute hypoxia injury model was established in HPPNCs. Cell counting kit-8 (CCK-8) assay was used to determine the optimal seeding density and hypoxic exposure duration. Proteomic analysis was utilized to identify differentially expressed proteins (DEPs) between normoxic and hypoxic conditions, followed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to identify affected biological pathways. Bioinformatics prediction (e.g, RPISeq prediction of RNA-protein interactions) was integrated with quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting to evaluate changes in DEPs and the lncRNA FTX/miR-137-3p axis. Small interfering RNA (siRNA) silencing and interaction potential prediction were further employed to confirm the regulatory role of lncRNA FTX. Results CCK-8 assay determined that the optimal seeding density for HPPNCs was 3.5×10³ cells·well⁻¹ and that 48 h of acute hypoxia exposure significantly reduced cell viability. Proteomic analysis revealed that DEPs were primarily enriched in the synaptic vesicle cycle pathway. Synaptosomal-associated protein 25 (SNAP25), a core component of the SNARE complex, was significantly downregulated at both mRNA and protein levels (P < 0.01). Mechanistic studies found that lncRNA FTX expression was significantly decreased in hypoxic cells, whereas miR-137-3p expression was significantly elevated. Furthermore, siRNA silencing of lncRNA FTX significantly reduced SNAP25 expression. RPISeq prediction suggested a potential interaction between lncRNA FTX and the SNAP25 protein (random forest, RF=0.75; support vector machine, SVM=0.56). Conclusion Acute hypoxia exposure may impair synaptic vesicle function in hippocampal neuronal cells by downregulating lncRNA FTX, increasing miR-137-3p expression, and suppressing SNAP25 expression, thereby disrupting the SNARE complex. These findings suggest that the lncRNA FTX/miR-137-3p/SNAP25 axis may play an important role in acute hypoxia-induced synaptic dysfunction.

To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts. After integrating the results of two studies, the genetic variations related to the platinum-based chemotherapy response were further determined by fine-mapping in 838 samples, and their potential functional impact were investigated by eQTL analysis and in vitro cell experiments. We found that a total of 68 variations were significant at P < 1 × 10^-3 in cohort 1 discovery stage, of which 3 SNPs were verified in 262 independent samples. A total of 541 SNPs were significant at P < 1 × 10^-4 in cohort 2 discovery stage, of which 8 SNPs were verified in 347 independent samples. Comparing the validated SNPs in two GWAS, ADCY1 gene was verified in both independent studies. The results of fine-mapping showed that the G allele carriers of ADCY1 rs2280496 and C allele carriers of rs189178649 were more likely to be resistant to platinum-based chemotherapy. In conclusion, our study found that rs2280496 and rs189178649 in ADCY1 gene were associated the sensitivity of platinum-based chemotherapy in NSCLC patients.